Navigation Links
Treatment Combo for Pancreatic Cancer Has Limited Benefit
Date:3/4/2008

Chemo/chemoradiation therapy extended survival but not significantly

TUESDAY, March 4 (HealthDay News) -- In patients who had surgery for pancreatic cancer, adding the chemotherapy drug gemcitabine to chemoradiation prolonged survival, but the improvement was not statistically significant, a new study finds.

Among patients who have surgery to remove pancreatic cancer, there is a 50 percent to 85 percent rate of local relapse and a five-year survival rate of less than 20 percent, according to background information in the study.

This makes the combination of added postoperative chemotherapy and radiation an important consideration. Previous research has shown that gemcitabine is more effective than the drug fluorouracil at improving patient outcomes.

This study examined whether the addition of gemcitabine to the supplemental treatment of fluorouracil chemoradiation improved survival in patients who had a portion of their pancreas removed as a treatment for pancreatic cancer.

During the study, the 451 patients received either chemotherapy with gemcitabine (221) or with fluorouracil (230) for three weeks prior to chemoradiation therapy and for 12 weeks after chemoradiation therapy (with fluorouracil).

Among the 388 patients with pancreatic head tumors, those in the gemcitabine group had a median (midpoint) survival of 20.5 months and a three-year survival rate of 31 percent, compared to 16.9 months and 22 percent among those in the fluorouracil group. The rates of certain level (grade 4) of hematologic (abnormalities in blood cell counts) toxicity were 1 percent in the fluorouracil group and 14 percent in the gemcitabine group.

There were no differences in neutropenia (a blood disorder), infection, or in the ability to complete chemotherapy or radiation therapy.

"The addition of gemcitabine to (supplemental) fluorouracil-based chemoradiation was associated with a survival benefit for patients with resected pancreatic cancer, although this improvement was not statistically significant," the study authors concluded.

The study was published in the March 5 issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 4, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New potential drug target for the treatment of atherosclerosis
2. New Treatment for Lazy Eye Shows Promise
3. New target for cancer therapy may improve treatment for solid tumors
4. ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
5. Customized treatments for sepsis lower treatment time and reduce length of ICU stays
6. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Geriatric Oncology Consortium (GOC) Announces Tampa Bay Road Rally to Raise Awareness for the Treatment of Seniors With Cancer
8. Comparison of antipsychotic treatments in adolescents with schizophrenia
9. Treatment for disease that affects estimated 1 in 2000 children gets them to eat again
10. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
11. Biomarkers for Mood May Alter Psychiatric Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2018)... ... ... Nutrex Research has launched a new series of weight loss ... Utilizing TopiSorbTM Technology, this gel quickly absorbs and targets subcutaneous and visceral fat via ... , Maximizing fat loss by applying topical treatments directly to areas of concern ...
(Date:11/16/2018)... ... November 16, 2018 , ... ... Framework (RMF) approved, cloud-based Force Protection and Emergency Management solutions who announced today ... contract to provide these services Army-wide. , Under the contract, E-9 will expand ...
(Date:11/16/2018)... ... November 16, 2018 , ... OnlineMasters.com, an industry-leading educational research ... for 2019. They have identified the top programs in the nation that are ... outcomes. , Leveraging an exclusive data set comprised of interviews and surveys from ...
(Date:11/15/2018)... ... November 15, 2018 , ... Modern Acupuncture™, the ... to people in an accessible and affordable delivery, is now open in Bothell. ... opening locations all across the country. , Located at 1427 228th Street in ...
(Date:11/15/2018)... , ... November 15, 2018 , ... Over the last ... has raised more than $1.7 million for National Breast Cancer Foundation (NBCF) . ... to enjoy a safer lifestyle. The proceeds have helped launch the National Mammography ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... 2018 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Pete Young, Director of Quality at Catalent’s Bolton, U.K. ... conference at the CCIB Convention Centre Barcelona, Barcelona, Spain on Nov. 27 – ...
(Date:11/15/2018)... ... November 15, 2018 , ... Triple W, an innovator of connected health ... the companion app for DFree®, the first wearable device for incontinence that notifies the ... children and disabled people with bladder control issues have a convenient and cost-effective alternative ...
(Date:11/15/2018)... NEW YORK (PRWEB) , ... November 15, 2018 ... ... for real world data, today announced that the company has been awarded a ... Institute (NCI) of the National Institutes of Health (NIH). , The pursuit of ...
Breaking Medicine Technology: